01 / PRODUCE
Expression & identity
Can the molecule be made reproducibly? Construct design, expression yield, purification recovery, identity and purity.
Explore assays ↗ THE EXPERIMENTAL PARTNER FOR AI BIOLOGICS
You've designed
the molecule.
Now prove it.
Turn AI-generated antibody and protein sequences into real, decision-grade experimental evidence. Expression, binding, stability, aggregation and early developability—a proposed coordinated workflow.
✓ Designed for VHHs, antibodies, scFvs & engineered proteins · Timelines confirmed case by case
Programs / AI-Designed Biologics / Lead characterization
Developability overview
Study S2S-024 · Example data only
LEAD CANDIDATES05Profiled in this study
ASSAY DIMENSIONS08Multi-parameter screen
DECISION STATUS02 / 05Priority candidates
Binding response · illustrative sensorgram
Candidate A Candidate B
CandidateAffinityMonomerStabilityAssessment
AB-018.4 nM98.3%67.2°C
AB-021.7 nM89.6%63.1°C
AB-0337 nM96.8%71.0°C
Illustrative UI — not actual experimental performanceRAW DATA + SCIENTIFIC CONTEXT →
✓
QUALITY-FIRST OUTPUTScientific decision support
AN EXPERIMENTAL REPORT, REIMAGINED
Go beyond the
data dump.
Explore what a candidate-level decision package could look like: linked assay readouts, transparent limitations, candidate comparisons, and an action-oriented scientific conclusion.
01 Evidence with context
02 Candidate-level risk view
03 Audit-friendly exports
Demonstration uses synthetic example data only. A live portal is not yet operational.
01 / WHY WE EXISTPrediction is a starting point.
Prediction is a starting point.
Evidence is the next step.
AI models can create hundreds of plausible biologics. But expression, kinetics, aggregation and stability still determine which molecules deserve the next experiment. We turn scattered tests into one scientific answer.
02 / CHARACTERIZE
Affinity & function
Does it interact with its intended target? Fit-for-purpose SPR/BLI kinetics and selected specificity or functional assays.
Explore assays ↗03 / DE-RISK
Stability & aggregation
Will it behave like a developable therapeutic? SEC, thermal stability, colloidal behavior and tailored stress tests.
Explore assays ↗02 / HOW IT WORKSFrom sequence to clarity.
From sequence to clarity.
Without the CRO maze.
A single point of scientific accountability, from assay selection through laboratory coordination, interpretation and final handoff.
01
↗
Tell us your goal
Share the modality, candidate count and decision you need to make. Sensitive sequences only after NDA and secure intake are arranged.
SCIENTIFIC SCOPING02
⌬
We plan & produce
Agree on the analytical panel, construct design, material requirements, acceptance criteria and delivery plan.
DESIGN & EXPRESSION03
⌁
We test & review
Coordinate expression and assays, assess data quality, flag unexpected findings and connect results across assays.
EXPERIMENTAL EVIDENCE04
✓
You move forward
Receive raw and processed data, an integrated risk readout and optional fit-for-purpose research material.
DECISION PACKAGETypical planning window: 4–12 weeksActual schedule depends on modality, sequence count, assay development and study-material needs.Plan a project ↗
03 / YOUR DELIVERABLENot another stack
Explore the sample report ↗Example layout only; no claimed client outcomes.
Not another stack
of assay files.
Your program needs an answer, not just chromatograms. We build an integrated scientific interpretation of the experimental results and their limitations.
01Raw data, fitted curves & QC metadata
02Side-by-side candidate comparison
03Prioritized liabilities & next-step recommendations
04Clear limitations and study-specific acceptance criteria
SEQ2STUDY / SAMPLEEXAMPLE • NOT CLIENT DATA
PRECLINICAL DEVELOPABILITYCandidate readiness
Candidate readiness
assessment
Biologics lead series · Integrated summary
DOMAINAB-01AB-02AB-03
Expression● Low risk● Review● Low risk
Binding● Low risk● Low risk● Review
Aggregation● Low risk● Elevated● Low risk
Stability● Low risk● Review● Low risk
04 / CONFIGURABLE PROGRAMSStart small. Go deep.
Start small. Go deep.
Make the right call.
Choose a starting point, then tailor the tests around the questions that matter to your development team.
01 / RAPID TRIAGE
Screen your
first designs.
Prioritize AI-generated candidates with core expression, purity, aggregation and binding information.
PLANNING RANGE$7.5k–$13kTypically 3–4 weeks
02 / DEVELOPABILITY 360
CORE OFFERINGKnow your
molecule deeply.
Integrated binding, physicochemical behavior and stability—organized into a candidate decision dossier.
PLANNING RANGE$24k–$38kTypically 6–8 weeks
03 / IN VIVO PREPARATION
Prepare for
the next study.
Tailored characterization and research-material readiness built around the intended nonclinical protocol.
PLANNING RANGE$35k–$70kTypically 8–12 weeks
Planning-only budget hypotheses, not formal quotations. Delivery and feasibility are reviewed individually. Research-use assessments do not replace GLP, GMP or IND-enabling requirements.
05 / SCOPE YOUR STUDYTell us what
Tell us what
you're building.
Start with the science, not a long email thread. Create a project brief based on your molecule, priorities and intended next step.
✳ Tailored assay selection, not a rigid checklist
✳ Transparent planning range before proposal
✳ No sequence upload at this stage
Confidentiality by design. This prototype works entirely in your browser. It does not transmit information, accept orders or receive confidential sequences. Formal projects require NDA, secure intake and an agreed SOW.
06 / COMMON QUESTIONSScience-first.
Science-first.
Clear on scope.
Designed for biologics teams who need experiment-backed answers before making larger development commitments.
Can we start with only a protein sequence?
Yes. We can review format and scientific goals before requesting confidential sequences. Actual project intake requires signed confidentiality terms and an approved secure transfer method.
Will the report tell us if our antibody is ready for in vivo studies?
It can inform the decision, including relevant material and quality risks. Readiness depends on the particular animal protocol, species cross-reactivity, formulation, dose and other study-specific factors. No universal “in vivo grade” certification is implied.
Can we customize the characterization panel?
Yes. Assay selection depends on modality and intended use. We can add orthogonal methods, cross-reactivity panels or research-material preparation as appropriate, subject to feasibility and formal scope.
Will our sequences be used to train AI models?
Our proposed policy is no model training on confidential customer sequences or results unless separately authorized. Actual project rights and subcontractor obligations must be agreed contractually.
BUILD CONFIDENCE BEFORE THE NEXT EXPERIMENTYour next decision
Start with a study brief ↗